X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (784) 784
male (555) 555
index medicus (549) 549
female (485) 485
hiv infections - drug therapy (484) 484
pharmacology & pharmacy (416) 416
adult (415) 415
efavirenz (392) 392
benzoxazines - pharmacokinetics (347) 347
pharmacokinetics (296) 296
infectious diseases (294) 294
benzoxazines (253) 253
anti-hiv agents - pharmacokinetics (249) 249
middle aged (249) 249
benzoxazines - administration & dosage (247) 247
benzoxazines - therapeutic use (245) 245
anti-hiv agents - therapeutic use (242) 242
hiv (229) 229
animals (185) 185
anti-hiv agents - administration & dosage (185) 185
drug interactions (184) 184
antiviral agents (179) 179
reverse transcriptase inhibitors - pharmacokinetics (160) 160
immunology (156) 156
reverse transcriptase inhibitors - therapeutic use (154) 154
antiretroviral therapy (153) 153
microbiology (153) 153
benzoxazines - blood (139) 139
benzoxazines - pharmacology (133) 133
benzoxazines - adverse effects (132) 132
pharmacogenetics (132) 132
drug therapy, combination (128) 128
therapy (122) 122
nevirapine (121) 121
treatment outcome (120) 120
anti-hiv agents - adverse effects (119) 119
young adult (115) 115
hiv infection (114) 114
hiv infections - virology (114) 114
oxazines - pharmacokinetics (110) 110
anti-hiv agents - blood (109) 109
drug therapy (109) 109
adolescent (106) 106
cyp2b6 (104) 104
virology (102) 102
antiretroviral drugs (97) 97
reverse transcriptase inhibitors - administration & dosage (95) 95
analysis (93) 93
dose-response relationship, drug (93) 93
hiv-infected patients (93) 93
research (93) 93
viral load (93) 93
rats (92) 92
cytochrome p-450 cyp2b6 (91) 91
human immunodeficiency virus--hiv (89) 89
oxazines - therapeutic use (89) 89
genotype (87) 87
hiv-1 - drug effects (87) 87
aryl hydrocarbon hydroxylases - genetics (86) 86
population pharmacokinetics (83) 83
hiv infections - blood (82) 82
hiv infections - complications (81) 81
pharmacology (78) 78
dosage and administration (77) 77
metabolism (77) 77
virus diseases (77) 77
article (75) 75
hiv-1 (75) 75
plasma-concentrations (75) 75
reverse transcriptase inhibitors - blood (75) 75
aids (74) 74
area under curve (74) 74
drug administration schedule (73) 73
hiv infections - genetics (72) 72
reverse transcriptase inhibitors - adverse effects (71) 71
hiv-1-infected patients (69) 69
aged (68) 68
tuberculosis (68) 68
protease inhibitors (67) 67
cd4 lymphocyte count (66) 66
child (65) 65
highly active antiretroviral therapy (65) 65
hiv infections - metabolism (65) 65
health aspects (64) 64
oxidoreductases, n-demethylating - genetics (64) 64
prospective studies (64) 64
aids/hiv (61) 61
reverse-transcriptase inhibitors (61) 61
nevirapine - therapeutic use (60) 60
ritonavir (60) 60
administration, oral (58) 58
individuals (58) 58
tenofovir (58) 58
mice (57) 57
oxazines - blood (57) 57
antiretroviral therapy, highly active (56) 56
oxazines - administration & dosage (56) 56
tuberculosis - drug therapy (56) 56
benzoxazines - chemistry (54) 54
child, preschool (54) 54
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 4/2008, Volume 64, Issue 4, pp. 357 - 365
The study sought to investigate the relationship between efavirenz exposure and the CYP2B6 516G→T(*6) genotype in HIV/AIDS outpatients, using pharmacokinetic... 
CYP2B6 polymorphism | HIV/AIDS patients | Biomedicine | Pharmacology/Toxicology | Pharmacokinetic modelling | Efavirenz | NONMEM | ADULTS | REGIMENS | DISCONTINUATION | AFRICA | pharmacokinetic modelling | REVERSE-TRANSCRIPTASE INHIBITORS | METABOLISM | INITIAL THERAPY | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | HIV-1 INFECTION | EXPRESSION | efavirenz | Oxidoreductases, N-Demethylating - genetics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Reverse Transcriptase Inhibitors - administration & dosage | Genetic Variation | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Female | Population | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - metabolism | Zimbabwe - epidemiology | Benzoxazines - administration & dosage | Gene Frequency | HIV Infections - genetics | HIV Infections - virology | Genotype | Models, Statistical | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Algorithms | Sex Factors | HIV Infections - drug therapy | Cytochrome P-450 CYP2B6 | HIV Infections - metabolism | Antiviral agents | Analysis | Drug interactions | Cytochrome P-450 | Models | HIV (Viruses) | Drug therapy | Anti-HIV agents | Genotype & phenotype | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Pharmacology | Drug dosages
Journal Article
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 07/2015, Volume 25, Issue 7, pp. 363 - 376
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 12/2012, Volume 51, Issue 12, pp. 809 - 822
Journal Article
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 06/2013, Volume 13, Issue 1, pp. 261 - 261
Background: HIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects. We evaluated the influence of rifampicin... 
CYP2B6 | Rifampicin | Tuberculosis | HIV | CNS | Ugandans | Efavirenz | Neuropsychiatric toxicity | Antiretroviral therapy | INFECTIOUS DISEASES | ANTITUBERCULAR THERAPY | SECONDARY METABOLISM | DRUG CONCENTRATIONS | HIV-1-INFECTED PATIENTS | BLOOD-BRAIN-BARRIER | NEUROPSYCHIATRIC ADVERSE EVENTS | PLASMA EXPOSURE | NEUROCOGNITIVE DISORDERS | INFECTED PATIENTS | Memory Disorders - virology | Prospective Studies | Humans | Mental Disorders - metabolism | Aryl Hydrocarbon Hydroxylases - genetics | Hallucinations - virology | Memory Disorders - metabolism | Uganda - epidemiology | HIV Infections - psychology | Male | Sleep Arousal Disorders - virology | HIV Infections - microbiology | Cytochrome P-450 CYP3A - genetics | Benzoxazines - pharmacokinetics | Sleep Arousal Disorders - metabolism | Tuberculosis - drug therapy | Adult | Benzoxazines - blood | Female | Rifampin - therapeutic use | Anti-HIV Agents - blood | Mental Disorders - virology | Tuberculosis - metabolism | Cognitive Dysfunction - drug therapy | Hallucinations - drug therapy | Cognitive Dysfunction - virology | Anti-HIV Agents - adverse effects | Cognitive Dysfunction - metabolism | Gene Frequency | Kaplan-Meier Estimate | Benzoxazines - adverse effects | Hallucinations - metabolism | Mental Disorders - microbiology | Antiretroviral Therapy, Highly Active | Tuberculosis - virology | Memory Disorders - drug therapy | Sleep Arousal Disorders - drug therapy | Mental Disorders - drug therapy | Anti-HIV Agents - pharmacokinetics | Antibiotics, Antitubercular - therapeutic use | HIV Infections - drug therapy | Cytochrome P-450 CYP2B6 | HIV Infections - metabolism | Sleep disorders | Usage | Hallucinations and illusions | Research | Analysis | Medical research | Antiviral agents | Care and treatment | Nervous system diseases | Pharmacogenetics | Cytochrome P-450 | HIV patients | HIV (Viruses) | Highly active antiretroviral therapy | Sleep | Insomnia | Medicine, Experimental | Health aspects | Rifampin | Plasma | Genotype & phenotype | Health sciences | Brain research | Blood-brain barrier | Human immunodeficiency virus--HIV | Drug therapy | Patients | Psykiatri | Farmakologi och toxikologi | Klinisk medicin | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Infektionsmedicin
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 9/2010, Volume 202, Issue 5, pp. 717 - 722
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2007, Volume 46, Issue 11, pp. 941 - 952
Objective: To characterise the interactions between tacrolimus and antiretroviral drug combinations in hepatitis C virus-HIV co-infected patients who had... 
Antiretrovirals | HIV infections | Tacrolimus | Ritonavir | Lopinavir | Nelfinavir | Liver transplant | Hepatitis C | Efavirenz | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Ritonavir, pharmacokinetics | Efavirenz, pharmacokinetics | Antiretrovirals, pharmacokinetics | Tacrolimus, pharmacokinetics | Lopinavir, pharmacokinetics | Nelfinavir, pharmacokinetics | REVERSE-TRANSCRIPTASE INHIBITORS | KIDNEY-TRANSPLANTATION | PROTEASE-INHIBITOR | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | HUMAN-IMMUNODEFICIENCY-VIRUS | CLINICAL PHARMACOKINETICS | DRUG-DRUG INTERACTIONS | CONSENSUS DOCUMENT | ORGAN-TRANSPLANTATION | NELFINAVIR | Hepatitis C - therapy | Liver Transplantation | Area Under Curve | Humans | Middle Aged | Half-Life | Male | HIV - drug effects | Dose-Response Relationship, Drug | Benzoxazines - pharmacokinetics | Ritonavir - therapeutic use | Adult | Benzoxazines - blood | Female | Hepatitis C - complications | Nelfinavir - therapeutic use | Tacrolimus - blood | Ritonavir - blood | Pyrimidinones - therapeutic use | CD4 Lymphocyte Count | Graft Rejection - diagnosis | Tacrolimus - pharmacokinetics | Nelfinavir - blood | Benzoxazines - therapeutic use | Antiretroviral Therapy, Highly Active | Tacrolimus - therapeutic use | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | HIV Infections - complications | HIV Infections - therapy | Aged | Nelfinavir - pharmacokinetics | Viral Load - methods
Journal Article
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 2012, Volume 67, Issue 9, pp. 2213 - 2221
Journal Article